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Review Article
In the time it takes to read this article, at least one person in the United States will have died from an opioid overdose.1 From 1999 through 2017, more than 700,000 U.S. residents died from a drug overdose; the major-
ity of these events involved an opioid.2 Among persons between the ages of 24 and 
34 years, one in five deaths is now related to opioid use.3
Every opioid-related death represents a missed opportunity for prevention. In 
this review, we focus on prescriber strategies for overdose prevention in three 
groups of patients: those who have not received previous opioid therapy, those 
receiving long-term opioid therapy, and those with an opioid use disorder.
R educing Ov er d ose R isk in Ini ti a l Opioid Ther a py
All opioid overdoses share a common characteristic: a first opioid exposure. Al-
though this exposure often occurs independent of a health care interaction (e.g., 
experimentation with a medication prescribed to a friend or relative), prescribers 
should strive “to keep opioid-naive patients opioid-naive.”4 For mild or moderate 
acute pain, nonopioid regimens are the preferred first-line therapy.
Limiting the Initial Dose and Duration
When acute moderate or severe pain necessitates the use of opioids, prescribers 
should limit the course to the lowest dose and shortest duration possible. Even 
brief opioid courses have potential long-term consequences. In some patients, 
physical dependence develops quickly, making cessation difficult.5 In patients who 
have not received previous opioid therapy, the risk of transitioning from short-term 
to long-term use begins to increase after the fifth day of exposure,6 especially in 
those receiving high doses or long-acting formulations.7 Yet, at their first primary 
care visit for pain, 46% of patients who were prescribed an opioid received enough 
for 7 days, and 10% received enough for 30 days.8 Prescribers are advised to be 
particularly cautious with adolescent patients. Receiving a provider-prescribed 
opioid before the 12th grade is independently associated with a 33% increase in 
the risk of nonmedical opioid use by the age of 23 years.9
New, persistent opioid use is increasingly recognized as one of the most com-
mon complications after elective surgery.10 In postoperative prescribing, adequate 
analgesia should be balanced against the risks that come with prolonged treat-
ment and provision of excessive quantities of the drug. Patients receiving an opioid 
prescription after short-stay surgery were 44% more likely to use opioids at 1 year 
than were patients who did not receive a prescription.11 Among adolescents and 
young adults who had not received previous opioid therapy, approximately 5% of 
those who were administered opioids postoperatively continued to receive them 90 
days later.12 Moreover, up to 71% of prescribed postoperative doses go unused.13 
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After laparoscopic cholecystectomy or hernior-
rhaphy, more than 80% of patients used fewer 
than 15 opioid doses (each typically containing 
5 mg of oxycodone or hydrocodone).14
Simply lowering the default prescription quan-
tity from 30 tablets to 12 reduced postproce-
dural opioid prescribing by 15% in one hospital 
system. This reduction was equivalent to approxi-
mately 25,000 fewer oxycodone tablets over a 
3-month period, with no significant increase in 
opioid refills, which suggested an absence of 
undertreated pain.15 An innovative and patient-
centered approach tailored the dose of analgesic 
drugs to individual opioid requirements during 
the 24 hours before hospital discharge, which 
obviated the need for an opioid prescription in 
41% of surgical patients.16
Assessing the Risks of Opioid Initiation
In theory, all patients who are treated with opi-
oids incur a risk of overdose. However, several 
factors increase that risk, including sleep-disor-
dered breathing, end-organ dysfunction leading 
to impaired medication clearance, pulmonary 
disease, and concomitant use of sedating medi-
cations. (Details are provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org.)
The number and severity of risk factors need 
to be considered to ensure that the benefits of 
prescription opioids clearly outweigh the risk of 
overdose. The revised Risk Index for Overdose 
or Severe Opioid-Induced Respiratory Depression 
(RIOSORD) is a validated instrument used to 
estimate the risk of overdose in opioid-treated 
patients (Table 1).17,18 The predicted probability 
of opioid-induced respiratory depression within 
6 months after initiation ranges from 1.9% in 
the lowest-risk group to 83.4% in the highest-
risk group (Table 2).17 Despite several practical 
limitations (including the length of the index 
and a lack of clinician familiarity), the use of 
RIOSORD can guide risk–benefit decisions and 
facilitate reassessment of risk over time.
Prescription drug monitoring programs 
 (PDMPs) allow the assessment of a patient’s pre-
scription opioid history, and a patient-specific 
query is required before opioid initiation in sev-
eral states. In areas without a legislative mandate, 
PDMP inquiries are infrequently completed; rec-
ognized obstacles include time, workload, and 
poor integration into existing electronic medical 
records.19 However, PDMPs can identify doctor 
shopping, concomitant benzodiazepine prescrip-
tions, and evidence of an undisclosed opioid use 
Question
Points for 
Positive 
Response
In the past 6 mo, has the patient had a health care visit (outpatient, 
inpatient, or emergency department) involving any of the fol-
lowing health conditions?†
Substance use disorder (abuse or dependence), including alcohol, 
amphetamines, antidepressants, cannabis, cocaine, hallucino­
gens, opioids, and sedatives
25
Bipolar disorder or schizophrenia 10
Stroke or other cerebrovascular disease  9
Kidney disease with clinically significant renal impairment  8
Heart failure  7
Nonmalignant pancreatic disease (e.g., acute or chronic pancreatitis)  7
Chronic pulmonary disease (e.g., emphysema, chronic bronchitis, 
asthma, pneumoconiosis, asbestosis)
 5
Recurrent headache (e.g., migraine)  5
Does the patient use any of the following substances?
Fentanyl 13
Morphine 11
Methadone 10
Hydromorphone  7
Does the patient use an extended-release or long-acting formula-
tion of any prescription opioid?‡
 5
Prescription benzodiazepine (e.g., diazepam, alprazolam)  9
Prescription antidepressant (e.g., fluoxetine, citalopram, venlafaxine, 
amitriptyline)
 8
Is the patient’s current maximum prescribed daily morphine-
equivalent dose ≥100 mg for all opioids used on a regular basis?
 7
Total possible score 146
*  This questionnaire was adapted from Zedler et al.17 with permission from Ox­
ford University Press. The index was validated in 36,166 patients (7234 cases 
and 28,932 controls) who received an opioid prescription from 2009 to 2013, 
as recorded in a claims database of a commercially insured health plan. Data 
on how scores were used to calculate the probability of respiratory depression 
are provided in Table 2.
†  The condition does not have to be the primary reason for the visit, but it should 
be entered in the chart or electronic health record as one of the reasons for the 
visit or diagnosis.
‡  Extended­release or long­acting formulations and certain opioid active ingredi­
ents were significantly and independently associated with the likelihood of 
overdose. As such, each formulation and each active ingredient are included 
and scored as independent factors in the risk index. For example, methadone 
and an extended­release formulation of fentanyl receive risk points for both 
the active ingredient and the formulation. A short­acting formulation of fentanyl 
receives points for the active ingredient only. Risk points for formulations are 
counted only once, regardless of the number of opioid products that the patient 
consumes.
Table 1. Risk Index for Overdose or Serious Opioid-Induced Respiratory 
Depression (RIOSORD).*
The New England Journal of Medicine 
Downloaded from nejm.org at UMass Medical School on June 7, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;23 nejm.org June 6, 20192248
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
disorder, such as previous receipt of buprenor-
phine prescriptions. These signals should prompt 
clinicians to screen for an opioid use disorder 
and offer treatment when present. This evalua-
tion can be accomplished through the Rapid 
Opioid Dependence Screen, which can be ad-
ministered in under 2 minutes.20
Promoting Disposal of Unused Doses
Diverted prescription opioids represent a com-
mon initial exposure for those with an opioid 
use disorder.21,22 Among adolescents and young 
adults, the risk of heroin initiation is 13 times 
as high in those with a history of nonmedical 
use of prescription opioids as in those without 
such a history.6 Counseling patients regarding 
recommended options for discarding their ex-
cess tablets improves safe disposal and reduces 
the risk of misuse by others.23 Medication dis-
posal boxes and community-based drug take-
back events offer alternatives to storing unused 
opioids at home.24 Flushing unused opioids 
down the toilet is practical and introduces neg-
ligible amounts of opioids into the environment 
relative to that contributed by human waste, 
although the practice is sometimes opposed on 
environmental grounds.25
R educing Ov er d ose R isk in 
L ong -Ter m Opioid Ther a py
The prescribing of opioids for chronic pain is 
not supported by strong evidence.26,27 For some 
patients, long-term opioid therapy delays recov-
ery, hinders functional improvement, or worsens 
pain through opioid-induced hyperalgesia.28-30 
Moreover, long-term opioid therapy carries clin-
ically significant risks, including sedation, depres-
sion, constipation, reduced libido, motor-vehicle 
collisions, sleep-disordered breathing, and acci-
dental overdose. Nonetheless, many patients and 
clinicians view opioids as a beneficial (and some-
times essential) element of chronic pain man-
agement. An underappreciated challenge with 
respect to such patients, particularly those re-
ceiving high doses, is ascertaining the extent to 
which the perceived benefits represent a genuine-
ly salutary effect of opioids rather than the de-
sire to avoid opioid withdrawal, which itself can 
produce pain and functional impairment.31
For patients with chronic pain, opioids should 
be an intervention of last resort when other drug 
and nondrug therapies have failed.27 When opioids 
are prescribed, the functional objectives of treat-
ment should be established at the outset of ther-
apy, with a clear plan to taper opioids if these 
goals are not met.
Avoiding Dose Escalation
Most adverse effects of opioids are related to 
dose, and guidelines caution against excessive 
dose escalation in the management of chronic 
pain except during end-of-life care.27 Morphine-
equivalent doses approximate equianalgesic doses 
of opioids of varying potency. Guidelines of both 
the Centers for Disease Control and Prevention 
(CDC)27 and its Canadian counterpart32 encour-
age maintaining the total daily morphine-equiv-
alent dose below 90 mg (and ideally <50 mg) in 
patients who are initiating long-term opioid 
therapy. A dose-dependent increase in the risk of 
a fatal overdose during long-term opioid therapy 
is well described33-37; death from opioid-related 
causes occurs in up to 3.8% of men and 2.2% of 
women who are prescribed a daily morphine-
equivalent dose of more than 200 mg.35
Decreasing High-Dose Opioid Use in Patients 
with Chronic Pain
Before the publication of guidelines on opioid 
prescribing for chronic pain, countless “legacy 
patients” had prescriptions that were progres-
sively escalated to high-dose opioids in an effort 
to overcome persistent pain. Abrupt dose reduc-
tion in these patients can lead to withdrawal-
Risk Class
RIOSORD 
Score
Average Predicted 
Probability
Actual Observed 
Incidence
percent
1 <5  1.9  2.1
2 5–7  4.8  5.4
3 8–9  6.8  6.3
4 10–17 15.1 14.2
5 18–25 29.8 32.2
6 26–41 55.1 58.8
7 ≥42 83.4 82.4
*  Data are from the study by Zedler et al.17 The study resulted in a model for scor­
ing of the risk of opioid­induced respiratory depression with a C­statistic of 0.90.
Table 2. Risk Classes and Predicted Probability of Serious Opioid-Induced 
Respiratory Depression during the Next 6 Months.*
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associated worsening of pain, insomnia, dyspho-
ria, a protracted abstinence syndrome, and even 
suicidality.38 Patients in whom doses are tapered 
too rapidly may seek alternate sources to alleviate 
withdrawal symptoms. Given the profusion of 
highly potent fentanyl analogues in the illicit 
drug supply, such rapid tapering could be fatal.38
In one study, more than 70% of the patients 
who were receiving long-term opioid therapy 
voluntarily participated in tapering when of-
fered.39 Clinicians should engage patients receiv-
ing high-dose opioids in shared decision making 
about the merits of gradual dose reduction — 
specifically, a more favorable balance of benefits 
versus harms. These discussions are frequently 
difficult. However, it can be helpful to explain 
that for many patients who taper gradually, pain 
does not worsen and often decreases.40,41 Expla-
nations for this finding include improvements in 
opioid-induced hyperalgesia, sedation, and mood.40 
Some patients are able to taper quickly, whereas 
others struggle with even minor dose reductions, 
which highlights the importance of an indi-
vidualized approach that tapers at the patient’s 
pace.42,43 Adjunctive therapies (e.g., clonidine) can 
be used to minimize withdrawal symptoms.
An alternative to gradual tapering involves 
transitioning patients from high-dose opioids to 
buprenorphine, a medication commonly used for 
the treatment of opioid use disorder (Table 3).44,45 
Buprenorphine is a high-affinity partial agonist 
at mu-opioid receptors that has a ceiling effect 
on sedation and respiratory depression without 
a clinically relevant ceiling on analgesia.46 As is 
the case with full opioid agonists, buprenorphine 
causes modest reductions in chronic pain, as com-
pared with placebo,47 whereas its anxiolytic and 
antidepressant effects may reflect antagonism at 
kappa-opioid receptors.48 Transitioning from full 
agonists to buprenorphine not only reduces the 
risk of accidental overdose but frequently im-
parts subjective improvements in pain, function, 
sleep, and constipation.49
Two buprenorphine formulations (transdermal 
and buccal) have been approved by the Food and 
Drug Administration for chronic pain, and other 
formulations have been used off-label for this 
indication. In the United States, any practitioner 
can prescribe buprenorphine for chronic pain 
without additional designation. However, special-
ized training (8 hours of online or in-person 
training for physicians; 24 hours for advanced 
Process Tapering Rotation to Buprenorphine
Indication Patient requests dose reduction, no clinically significant 
improvement in pain or function despite opioid 
treatment, >90 mg MED or lower dose in conjunction 
with benzodiazepine or other sedating medication, 
having opioid­related adverse events, nonadherence 
to treatment plan, medical conditions conferring in­
creased risk of overdose
Patient requests transition to buprenorphine, no clinical­
ly significant improvement in pain or function despite 
opioid treatment, concern that opioid­induced hyper­
algesia is contributing to pain, nonadherence to treat­
ment plan, medical conditions conferring increased 
risk of overdose, coexisting chronic pain and opioid 
use disorder
Strategy Option A: If the patient is receiving multiple opioids, 
consolidate and switch all opioids to one new, 
 extended­release oral opioid; decrease the dose  
to account for incomplete cross­tolerance
Option B: If the patient is receiving multiple opioids,  
ask which opioid the patient would feel more com­
fortable tapering first
Patients must abstain from opioid agonists for at least  
8 to 12 hr (best accomplished overnight) and be in 
mild­to­moderate withdrawal (a score of ≥8 on the 
Clinical Opiate Withdrawal Scale)†
Speed Rapid taper: Reduce dose by 5 to 10% every 2 to 4 wk; 
continue taper over weeks to months
Slow taper: Reduce dose by 2 to 10% every 4 to 8 wk 
with pauses in taper, as needed; continue taper  
over months to years
Once a patient is having mild­to­moderate withdrawal, 
administer 2 to 4 mg of sublingual buprenorphine or 
buprenorphine plus naloxone. If patient has no unac­
ceptable side effects, administer an additional 4–8 mg 
sublingually at 1–2 hr, followed by adjustment accord­
ing to response up to 32 mg daily in divided doses
*  Listed are strategies for deciding between dose tapering or rotation to buprenorphine in patients who are receiving opioids for the treat­
ment of chronic pain. Details regarding requirements for prescribing of buprenorphine in patients with opioid use disorder in the United 
States are provided in Table 4. MED denotes morphine­equivalent dose.
†  Scores on the 11­item Clinical Opiate Withdrawal Scale indicate the following severity of symptoms: a score of 5 to 12, mild; 13 to 24, mod­
erate; 25 to 36, moderately severe; and more than 36, severe.
Table 3. Tapering Strategies and Rotation to Buprenorphine for Patients Receiving Opioids for Chronic Pain.*
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practice providers) and Drug Enforcement Agency 
registration are required to prescribe buprenor-
phine for opioid use disorder (Table 4).50-52
Minimizing the Use of Other Sedating 
Medications
In patients receiving long-term opioid therapy, 
the risk of overdose increases dramatically when 
benzodiazepines, muscle relaxants, gabapenti-
noids, or other central nervous system depres-
sants are coprescribed.53,54 There is now wide-
spread recognition that coprescribing of opioids 
and benzodiazepines is hazardous. Nevertheless, 
27% of veterans who received opioids also re-
ceived benzodiazepines, and the risk of overdose 
death was nearly four times as high in those 
using the two concurrently.53 Although gabapen-
tinoids are frequently used in an “opioid-sparing” 
approach, the concomitant use of gabapentin 
with opioids doubles the risk of fatal overdose as 
compared with the use of opioids alone.54 A 
similar dose-dependent risk is seen with prega-
balin.55 When opioids must be prescribed with 
other sedating medications, doses of all agents 
should be kept as low as possible to minimize 
the risk of overdose.
Monitoring for Evidence of Opioid Use 
Disorder
Opioid use disorder is a recognized complica-
tion of long-term opioid therapy. Several studies 
suggest that features of opioid use disorder are 
present in more than 25% of patients receiving 
opioids for chronic pain.56-58 Hallmarks of opioid 
use disorder include emotional volatility and 
signs of problematic medication use, such as 
taking more medication than prescribed, using 
opioids for reasons other than pain, and fre-
quent loss of medication or early refills. Some 
patients with chronic pain may conceal or dis-
avow features of opioid use disorder because of 
stigma or fear of losing access to prescribed 
opioids. Surveillance for opioid use disorder in 
patients with chronic pain includes pill counts, 
PDMP checks, and urine screening to assess 
adherence and check for the presence of unex-
pected drugs.
Several instruments are used clinically to 
screen for opioid use disorder.59 One of the sim-
plest is a validated, single-question instrument 
that asks, “How many times in the past year 
have you used an illegal drug or a prescription T
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medication for nonmedical reasons?” Any num-
ber greater than zero is considered a positive 
result.60 Prescribers can then opt for a more in-
depth survey instrument, such as the Current 
Opioid Misuse Measure, to further characterize 
features of opioid use disorder in patients receiv-
ing long-term opioids.61
Patients who have positive results on screen-
ing for features of opioid use disorder should 
not be denied opioid analgesia when other 
therapies are inappropriate. When the initiation 
of prescription opioids in patients with opioid 
use disorder is unavoidable, prescribers should 
have a very careful risk–benefit discussion, ac-
knowledging the risks of problematic medica-
tion use, establishing the goals of care, and 
planning follow-up with addiction or pain-man-
agement specialists whenever available. In these 
cases, buprenorphine may be an ideal choice for 
both analgesia and treatment of opioid use dis-
order.42
Clinicians sometimes find that providing treat-
ment for this patient population is challenging, 
but opioid use disorder in patients with chronic 
pain is an indication for more care rather than 
less. A punitive approach, such as dismissal from 
care, is counterproductive and places patients at 
greater risk for overdose if they transition from 
pharmaceutical opioids to illicit ones. Instead, 
recognizing the underlying opioid use disorder 
and arranging appropriate treatment are essential.
Naloxone for Patients with Chronic Pain
Coprescribing of naloxone is increasingly accept-
ed as a valuable tool in patients who are taking 
opioids for chronic pain. In a large observa-
tional study involving patients who were receiv-
ing long-term opioid therapy, those who were 
prescribed naloxone and provided with informa-
tion on the risk of overdose had 63% fewer 
emergency department visits at 1 year than those 
who did not receive such treatment.62 Naloxone 
is generally well received by patients and pre-
scribers in the primary care setting.63,64 The CDC 
guideline recommends coprescription of nalox-
one when patients who have a history of over-
dose or substance use disorder are prescribed 
opioids; it is also recommended in patients who 
are receiving a daily morphine-equivalent dose 
of more than 50 mg and in those receiving ben-
zodiazepines concurrently.27
Several naloxone formulations that differ in 
dose, route of administration, and cost are avail-
able (see the Supplementary Appendix). Of these 
formulations, intranasal naloxone (at a dose of 
4 mg) offers effectiveness and ease of adminis-
tration for patients receiving long-term opioid 
therapy. Excellent resources for guiding patient 
and family conversations on naloxone coprescrib-
ing are available online.65
R educing Ov er d ose R isk  
in Opioid Use Disor der
In 2016, the Substance Abuse and Mental Health 
Services Administration indicated that an esti-
mated 2.1 million U.S. residents had an opioid 
use disorder.66 Several strategies have been shown 
to decrease the risk of fatal overdose in these 
patients, including medications for the treatment 
of opioid use disorder and community efforts to 
distribute naloxone.
Medications for Opioid Use Disorder
Methadone and buprenorphine are the primary 
opioid agonists for the treatment of opioid use 
disorder, and their importance in overdose pre-
vention cannot be overstated. They promote re-
tention in treatment, reduce the use of illicit 
drugs, and consistently decrease mortality in 
patients with opioid use disorder.67-69 The choice 
of opioid agonist is based on a patient’s history, 
preferences, and access to care. Retention in a 
medication-based treatment program is better 
with methadone (a full opioid agonist) than with 
buprenorphine (a partial agonist).70,71 In the United 
States, special requirements exist regarding the 
prescribing of methadone and buprenorphine for 
opioid use disorder (Table 4).
When patients discontinue opioid use (e.g., 
detoxification with so-called drug-free protocols 
or during incarceration), the risk of death rises 
abruptly owing to loss of tolerance if they re-
sume drug use.72 As such, both the initiation of 
medications for opioid use disorder and subse-
quent efforts to maintain engagement with treat-
ment are essential to overdose prevention.67 A 
prolonged period without opioid use (including 
methadone and buprenorphine) is both a sign of 
recovery and a risk factor for fatal overdose. Al-
though some patients with opioid use disorder 
avoid using drugs for extended periods, resump-
tion of drug use is common and extremely peril-
ous, a factor that underlines the importance of 
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treatment with agonists such as methadone or 
buprenorphine. Both of these drugs mitigate 
cravings, and buprenorphine also lessens the risk 
of respiratory depression. The emphasis by prac-
titioners on abstinence-based recovery and the 
erroneous perception that opioid-agonist treat-
ment replaces one addiction with another are 
not based on evidence and pose potentially fatal 
risks to patients with opioid use disorder. In ad-
dition, patients’ engagement with treatment for 
opioid use disorder facilitates improved health 
care more generally, including screening and 
treatment for hepatitis C and human immuno-
deficiency virus infection.
Extended-release naltrexone, which is admin-
istered as a monthly intramuscular injection, is 
another option for patients with opioid use dis-
order. However, both the evidence base and clini-
cal experience with this formulation are limited.69 
In contrast to buprenorphine and methadone, 
naltrexone blocks mu-opioid receptors and con-
sequently the euphoric effects of opioids. The 
primary barriers to the use of extended-release 
naltrexone include the prolonged period of opi-
oid abstinence before initiation (typically, 7 to 10 
days) to avoid precipitation of withdrawal and 
the inability to later use opioids for analgesia, if 
necessary. As compared with buprenorphine or 
methadone, naltrexone is not associated with a 
reduced risk of opioid-related or all-cause death.68 
However, in persons who were recently released 
from incarceration, administration of extended-
release naltrexone was associated with a marked 
reduction in overdose events.73 Naltrexone re-
mains an important option for patients who 
decline, or do not have access to, opioid agonist 
treatment.
Community Programs for Naloxone 
Distribution
In 2018, the U.S. Surgeon General called on 
residents to carry naloxone with the goal of in-
creasing the availability of the antidote.1 Naloxone-
distribution programs for bystanders are safe 
and cost-effective interventions to decrease over-
dose deaths.74 Good Samaritan laws that offer 
legal protection to bystanders who give assis-
tance during an overdose are associated with 
lower rates of death from opioid overdose.75
Patients with an opioid overdose require im-
mediate restoration of ventilation and oxygen-
ation through artificial means (e.g., rescue 
breathing and endotracheal intubation) or rever-
sal of opioid-induced respiratory depression with 
naloxone.76 In many cases, the timely adminis-
tration of naloxone is sufficient to counter life-
threatening respiratory depression. The effect of 
high-potency fentanyl analogues is reflected in 
the evolution of bystander naloxone kits to in-
clude the provision of higher doses (up to 8 mg 
administered intranasally) than were historically 
supplied (see the Supplementary Appendix). After 
naloxone administration, respiratory depression 
will recur if the opioid effects outlast those of 
naloxone (typically, 30 to 90 minutes).76 Thus, 
persons who receive naloxone should be trans-
ported to the hospital for immediate follow-up 
care, as well as for qualified addiction care after 
overdose.
Care of Patients after Overdose
Nonfatal opioid overdose is a strong predictor of 
increased short-term mortality. From 2011 through 
2015, among persons in Massachusetts who had 
a nonfatal overdose, 6.2% died of an opioid-
related overdose within 1 year and 9.3% within 
2 years.77 Patients who see a clinician after an 
opioid overdose should be screened for suicidal 
ideation, since the association between opioid use 
disorder and suicidality remains underrecog-
nized.78 After a nonfatal overdose, treatment with 
methadone or buprenorphine reduced opioid-
related mortality by 59% and 38%, respectively; 
however, the majority of patients received nei-
ther drug.68 Initiation of buprenorphine in the 
emergency department represents a key oppor-
tunity to treat opioid use disorder and to de-
crease mortality.59 In addition, emergency initia-
tion of buprenorphine increases engagement with 
addiction treatment, as compared with brief in-
tervention and referral to treatment.79 Although 
buprenorphine diversion occurs frequently among 
patients who are being treated for opioid use 
disorder, typical motivations for diversion in-
clude the treatment of withdrawal symptoms 
and self-treatment of opioid use disorder; both 
motivations are more common than use with the 
intent of “getting high.”80
Public Policy and Harm-Reduction Strategies
Strategies for reducing harm aim to decrease the 
adverse health and social consequences associ-
ated with drug use. For example, several coun-
tries have embraced supervised injection facili-
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ties to prevent overdose, engage high-risk drug 
users, reduce health care use, decrease criminal 
activity, and reduce public drug use, needle shar-
ing, and the associated litter.81,82 For a subgroup 
of entrenched drug users, additional strategies 
to decrease opioid-associated deaths include super-
vised injection of heroin (diacetylmorphine)83 and 
decriminalization of small amounts of drugs for 
personal use in conjunction with expanded ac-
cess to addiction treatment. These strategies 
sensibly approach drug use as a health problem 
rather than a criminal one. (Details about this 
strategy are provided in the Supplementary Ap-
pendix.)
Conclusions
Several strategies reduce the risk of opioid over-
dose in diverse patient populations. Prescribers 
must carefully weigh potential benefits against 
the risks of opioid-related adverse events and 
overdose for all encounters involving prescription 
opioids. Patients receiving long-term high-dose 
opioid treatment should be counseled about steps 
to reduce the risk of overdose. Patients with an 
opioid use disorder require specialized treat-
ment, including ready access to opioid-agonist 
therapy, qualified addiction care, and a much 
greater emphasis on harm reduction, in the rec-
ognition that drug use is a common, yet treat-
able, health issue.
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